MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

NCT ID: NCT03504683

Last Updated: 2025-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-17

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One in three American adults have prediabetes, and up to 70% of adults with prediabetes eventually develop type 2 diabetes. With the high cost of treating diabetes, cost-effective approaches are needed to reduce the incidence of diabetes. One new strategy may be to change when people eat. Studies in rodents suggest that a form of intermittent fasting that limits eating to a short time period each day and involves fasting for the rest of the day (time-restricted eating; TRE) improves blood sugar control and cardiovascular health. Preliminary studies suggest that TRE also improves blood sugar, weight loss, and cardiovascular health in humans. This study will be the first full-scale, controlled feeding trial to determine whether TRE can improve 24-hour blood sugar control, 24-hour blood pressure, and cardiovascular disease risk factors even when food intake is matched to the control group. This clinical trial will also determine whether the benefits of TRE depend on the time of day that people eat. Participants will be assigned to one of three groups: (1) 'Early TRE' (eat between \~8 am-3 pm), (2) 'Mid-day TRE' (eat between \~1 pm - 8 pm), or (3) Control Schedule (\~8 am - 8 pm) for 8 weeks. All food will be provided and matched between groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PreDiabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomization will be stratified by fasting insulin. Within the lowest insulin strata, randomization will be further stratified by biological sex.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early TRE

Group Type EXPERIMENTAL

Early TRE

Intervention Type BEHAVIORAL

Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)

Mid-day TRE

Group Type EXPERIMENTAL

Mid-day TRE

Intervention Type BEHAVIORAL

Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)

Control Schedule

Group Type PLACEBO_COMPARATOR

Control Schedule

Intervention Type BEHAVIORAL

Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early TRE

Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)

Intervention Type BEHAVIORAL

Mid-day TRE

Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)

Intervention Type BEHAVIORAL

Control Schedule

Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

eTRE mTRE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 30-70 years old
* Prediabetic as determined by HbA1c between 5.7-6.4% or fasting glucose between 100-125 mg/dl with HbA1c \>= 5.1%
* Fasting insulin less than 100.0 mU/l and, if HbA1c \<5.7%, must also have fasting insulin \>= 8.0 mU/l
* BMI between 30-60 kg/m\^2
* Wake up at a regular time between 5-8 am

Exclusion Criteria

* Been diagnosed with diabetes or on diabetes medication or any medication known to affect glucose or 24-hour rhythms in blood pressure
* On weight loss medication
* Change in the dosage of a chronic medication within the past 2 months
* Have a clinically significant laboratory abnormality (e.g., abnormal hemoglobin levels)
* Significant gastrointestinal disease, major gastrointestinal surgery, or gallstones
* Significant cardiovascular, renal, cardiac, liver, lung, adrenal, or nervous system disease that might compromise the participant's safety or data validity
* Evidence of cancer (other than non-melanoma skin cancer) within the last 5 years
* Pregnant or breastfeeding
* Diagnosed psychiatric conditions
* Sleep disorder, circadian disorder, or regularly sleep less than 6 hours per night
* Major change in health or medical history in the past 3 months
* Currently perform overnight shift work
* Regularly eat within a \<10.5-hour period each day
* Lost or gained more than 4% of weight in the past 2 months
* Traveled more than 2 time zones away in the 2 months prior to enrolling in this study
* Will travel outside the Central time zone in the 2 weeks prior to testing
* Will travel more than 1 time zone away during this study
* Behavioral factors or other circumstances that may make it difficult for you to follow the study requirements
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Courtney M Peterson

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Courtney M. Peterson, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Courtney M. Peterson, Ph.D.

Role: CONTACT

205-934-0122

Harper Basquill, B.S.N.

Role: CONTACT

205-934-5458

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Brittany Tanner, B.S.

Role: primary

205-975-3944

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01DK118236

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB-300001180

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Meal Timing and Blood Pressure
NCT04133701 COMPLETED NA
Circadian Time Restricted Eating
NCT05628012 RECRUITING NA
A Study of Time Restricted Eating in Obese Adults
NCT05660291 ACTIVE_NOT_RECRUITING NA